Cyclin B1 is the regulatory subunit of cyclin-dependent kinase 1 (Cdk1) and is critical for the initiation of mitosis. Accumulating data indicate that the deregulation of cyclin B1 is tightly linked to neoplastic transformation. To study the phenotype and the potential preclinical relevance, we generated HeLa cell lines stably transfected with the plasmids encompassing short hairpin RNA (shRNA) targeting cyclin B1. We demonstrate that the reduction of cyclin B1 caused inhibition of proliferation by arresting cells in G2 phase and by inducing apoptosis. Cells, entering mitosis, were impaired in chromosome condensation and alignment. Importantly, HeLa cells with reduced cyclin B1 were more susceptible to the treatment of small interfering RNA targeting Polo-like kinase 1 (Plk1) and to the administration of the chemotherapeutic agent taxol. Finally, HeLa cells with reduced cyclin B1 showed inhibited tumor growth in nude mice compared to that of control cells. In summary, our data indicate that cyclin B1 is an essential molecule for tumor cell survival and aggressive proliferation, suggesting that the downregulation of cyclin B1, especially in combination with other molecular targets, might become an interesting strategy for antitumor intervention.
Introduction
The human B-type class of cyclins consists of three closely related members, cyclins B1, B2 and B3, which control the G2/M transition through combination with the Cdk protein kinases (Pines and Hunter, 1989; Glotzer et al., 1991) . Among these, cyclin B1 is the best studied and characterized member of the cyclin B family. Activation of the cyclin-dependent kinase 1 (Cdk1) only occurs when sufficient cyclin B1 protein has been synthesized (Solomon et al., 1990) . The cell cycledependent expression of cyclin B1 is critical for the proper timing of entry into mitosis.
During interphase, the Cdk1/cyclin B1 complex shuttles continually in and out of the nucleus. At the time of entry into mitosis, the four serine residues within the cytoplasmic retention signal (CRS) of cyclin B1 are phosphorylated, preventing the binding of the nuclear export factor, CRM1 (Li et al., 1997; Toyoshima et al., 1998; Yang et al., 1998 Yang et al., , 2001 Hagting et al., 1998) . Thus, the import rate is increased, whereas the export rate is decreased, leading to a rapid nuclear accumulation of Cdk1/cyclin B1. The studies from our lab and others demonstrate that Polo-like kinase 1 (Plk1) is the kinase responsible for the phosphorylation of Ser-133 (Yuan et al., 2002a; Jackman et al., 2003; Walsh et al., 2003) , which is required along with the phosphorylation of other three serine residues of CRS by Cdk1/cyclin B1 itself and other kinases like MAPK, for the accelerated nuclear import of Cdk1/cyclin B1 characteristic for the G2/M transition.
Emerging data imply that the deregulated expression of cyclin B1 is closely associated with neoplastic transformation. In normal cells, the accumulation of cyclin B1 protein begins at the S phase, reaches the maximal level at the onset of mitosis, and is then rapidly degraded at the metaphase-anaphase transition (Norbury and Nurse, 1992; Lehner and O'Farrell, 1990) . In contrast, cyclin B1 is already richly present even in the G1 phase in tumor cells such as HeLa cells and leukemia cell lines as well as in primary tumor tissues (Viallard et al., 1999; Shen et al., 2004) . Moreover, by applying immunostaining or Western blot analysis, overexpression of cyclin B1 has been reported in various malignant tumors (Soria et al., 2000; Hassan et al., 2001 Hassan et al., , 2002 Korenaga et al., 2002; Takeno et al., 2002; Yasuda et al., 2002; Yoshida et al., 2004) . The continuous and sustained expression of cyclin B1 in the G1 phase may exert its function by binding to its partner Cdks, which phosphorylate a series of substrates regardless of the phase in the cell cycle and contribute to the deregulated cellular proliferation in neoplastic tissues.
It has been reported that one of the consequences of overactivation of Cdk1/cyclin B1 is to override the G2 DNA damage checkpoint (Kao et al., 1997; Jin et al., 1998; Taylor et al., 1999; Park et al., 2000) , which leads to an accumulation of genomic defect, one hallmark of neoplastic development. Interestingly, a study revealed that overexpression of B-type cyclins alters chromosomal segregation (Sarafan-Vasseur et al., 2002) . More strikingly, enforced expression of cyclin B1 induces tetraploidy, either after mitotic spindle inhibition or in the absence of such inhibition if cyclin B1 is coexpressed with c-Myc (Yin et al., 2001) . Taken together, the uncontrolled expression of cyclin B1, caused by different mechanisms, is involved in the neoplastic transformation and promotes the proliferation of tumor cells. Thus, targeting cyclin B1 could become a promising intervention for potential antitumor therapy.
In the present work, we examine the phenotype and preclinical relevance of downregulation of cyclin B1 in human cervical carcinoma HeLa cells that harbor an RNA interference system as a stably integrated cassette for the expression of short hairpin RNA (shRNA) targeting cyclin B1.
Results

shRNA-mediated inhibition of cyclin B1 expression
In a previous report, we used small interfering RNAs (siRNAs) targeting cyclin B1 to knockdown endogenous gene expression (Yuan et al., 2004 ). Yet, the major disadvantage of this strategy is the short duration of the silencing effect. In order to study the long-term growth pattern of tumor cells in vitro and in vivo, we used the human H1 promoter to drive the expression of shRNA targeting cyclin B1 for the generation of a vector-based system (phH1/shRNA/cyclin B1). phH1/shRNA/green fluorescent protein (GFP) was prepared as a control plasmid. Each construct produced a shRNA composed of two 21-nucleotides in an inverted orientation as shown in Figure 1A .
phH1/shRNA/cyclin B1 and phH1/shRNA/GFP were transfected into HeLa cells. The cells were further cultured in selective medium. After 6 weeks, the cell clones were selected and seeded for further expansion in selective medium for Western blotting analysis. Cell clones with different remaining cyclin B1 levels were observed, as illustrated in Figure 1B . While the protein level of cyclin B1 of the cell clone HeLa 776-6, termed according to the targeting position of shRNA in cyclin B1 mRNA, was almost abolished (0.7%), HeLa 776-7 and HeLa 776-3 still displayed 13 and 52% of cyclin B1, respectively, compared to the protein level of cyclin B1 in control HeLa mock cells expressing shRNA against GFP. In contrast to cyclin B1, b-actin was not affected. The protein level of Cdk1 (Cdc2), the catalytic partner of cyclin B1, remained almost the same, indicating that the reduction of cyclin B1 by applying H1-driven shRNA constructs was specific. The reduction of cyclin B1 protein level in HeLa 776-6 cells could be also verified by immunostaining using specific antibodies against cyclin B1 ( Figure 1C, d ), compared to normal expression of cyclin B1 in control clone HeLa mock ( Figure 1C, c) . As shown in Figure 1C (h), an early metaphase cell from HeLa 776-6 clone displayed only weak staining of cyclin B1, whereas a late G2 phase cell and a metaphase cell from control HeLa mock clone exhibited a strong signal of cyclin B1 ( Figure 1C, g ). Moreover, HeLa 776-6 cells were analysed for the genomic integration of the above-described RNA interference cassettes. A PCR-based sequence analysis confirmed the integrity of the H1 promoter elements driving the expression of shRNA/cyclin B1 in HeLa 776-6 cells (data not shown).
Furthermore, the kinase activity of Cdk1/cyclin B1 was decreased in the cellular extracts from the stable clone HeLa 776-6 compared with the extracts from control clone HeLa mock ( Figure 1D ). The kinase activity of Cdk1/cyclin B1 in HeLa 776-6 after synchronization with thymidine-nocodazole reached only the basic levels of the kinase activity in nonsynchronized HeLa or HeLa mock cells ( Figure 1D , lower panel).
Regulators of G2/M in HeLa cells stably expressing shRNA/cyclin B1 We were next interested in the status of other important molecules involved in the regulation of G2/M transition after cyclin B1 is downregulated in the stably transfected HeLa cells. Two clones were selected for Western blot analysis after the synchronization with double-thymidine or thymidine-nocodazole: HeLa 776-6, in which cyclin B1 shows the strongest downregulation, and clone HeLa 776-7, which contains 13% of cyclin B1 in comparison with control HeLa mock clone (Figure 2 ). We could not observe any considerable change in protein levels of Cdk1 (Figure 2a ), Cdc25C (Figure 2b ), Polo-like kinase 1 (Plk1, Figure 2c ), cyclin A (Figure 2d ), indicating that the reduction of cyclin B1 by RNA interference is specific. Downregulation of cyclin B1 arrested HeLa cells in G2 phase and generated abnormal chromosomes Cyclin B1, combined with its catalytic subunit Cdk1, is responsible for the transition from G2 to M phase. To address the question whether the ability of mitosis entry correlates with reduced cyclin B1, HeLa 776-6 cells were synchronized to G1/S boundary by double-thymidine block and subsequently released to fresh medium. At indicated time points the cells were harvested and the distributions of cell cycle population were examined by FACS analysis ( Figure 3A ). We could not observe an obvious different distribution of G2/M phase between HeLa 776-6 and its control partner HeLa mock cells, except for a slight accumulation of G2/M phase cells of HeLa 776-6 cells 10 h after the release from the doublethymidine block ( Figure 3A ). Since the conventional FACS analysis cannot differentiate G2 phase from M phase, treated cells were further stained with bisbenzimide and antibodies against b-tubulin, and mitotic cells were counted with the help of an immunofluorescense microscope. As illustrated in Figure 3B , a strong reduction of the mitotic population was detected in HeLa 776-6 cells, indicating the reduction of cyclin B1 induced the cells arresting in G2 phase.
One of the most important functions of Cdk1/cyclin B1 is to condense and align the chromosomes properly for metaphase. We investigated the next step the chromosome morphologies of HeLa 776-6 cells. As illustrated in Figure 3C , cells, which could manage to enter into mitosis, displayed very often abnormal chromosomal morphologies, including impairment in chromosome condensation in early mitosis ( Figure 3C , a and d) and abnormal alignment in metaphase ( Figure  3C , b and c).
Reduction of cyclin B1 induced continuous apoptosis, inhibited proliferation and impaired the colony forming ability in HeLa 776-6 cells Furthermore, apoptosis studies using annexin V and propidium iodide staining exhibited a strong induction in early stage apoptosis (annexin V staining positive) as well as in late stage apoptosis (annexin V and propidium iodide double staining positive) in clone HeLa 776-6, as depicted in Figure 4A . This result could also be verified with DNA staining by showing the typical apoptotic morphologies, such as condensed and fragmented DNA ( Figure 4B ), whereas no apoptotic alteration could be observed in control HeLa mock cells (data not shown). Interestingly, survivin and XIAP (X-chromosomelinked inhibitor of apoptosis), two important suppressors of the apoptosis pathways, were reduced in HeLa 776-6, compared to control HeLa mock expressing shRNA against GFP ( Figure 4C and D). Collectively, Phenotype and in vivo relevance of the reduction of cyclin B1 J Yuan et al the data suggest that the reduction of cyclin B1 results in a sustained apoptosis. Since the reduction of cyclin B1 arrested cells in G2 phase and induced sustained apoptosis, we subsequently investigated the impact of the stable downregulation of cyclin B1 on the rate of cell proliferation. As expected, compared to control HeLa cells, the reduction of proliferation in clone HeLa 776-6 was up to 23, 43, 37 and 49%, at the time point 24, 48, 72 and 96 h, respectively (Figure 5a ). In control HeLa mock clone, the proliferation rate was almost not affected ( Figure 5a ).
Moreover, anchorage independent cell growth is one of the hallmarks of malignant tumor cells. Since uncontrolled cyclin B1 is involved in the process of neoplasmic transformation, we performed colony assays to evaluate the ability of cyclin B1 reduced HeLa cell clones. As shown in Figure 5b , the colony number of clone HeLa 776-6 was reduced up to 50%, compared to control HeLa mock cells.
HeLa 776-6 cells were susceptible to the treatment of siRNA targeting Plk1 or chemotherapeutic agent taxol Besides Cdk1/cyclin B1, Plk1 is also indispensable for mitosis entry and for progression through mitosis. Plk1 is an activator of Cdc25-Cdk1/cyclin B positive feedback loop and regulates multiple stages of mitosis. We have reported previously that Plk1 binds cyclin B1 and phosphorylates S133 of cyclin B1, which contributes in part to accelerating the nuclear translocation of Cdk1/ cyclin B1 (Yuan et al., 2002a) . Studies also demonstrate that the depletion/reduction of Plk1 inhibits the proliferation of tumor cells (Liu and Erikson, 2002; Spankuch-Schmitt et al., 2002; Yuan et al., 2002b; Spankuch et al., 2004) . Thus, Plk1, like cyclin B1, is required for tumor cell survival (Eckerdt et al., 2005) . We wondered whether the downregulation of both cyclin B1 and Plk1 could inhibit proliferation of tumor cells in a synergistic manner. In order to address this question, we treated the cell clone HeLa 776-6 with siRNA targeting Plk1 (siPlk) or its control siRNA against GFP (siGFP). As shown in Figure 6a , with low concentration 100 pM of siPlk, cell division was reduced by 20%. Over 50% inhibition was demonstrated with 10 nM siPlk. In the control cell clone HeLa mock, the inhibitory response was also observed, but in a less extent, especially with a low concentration 100 pM of siPlk. Furthermore, more apoptotic cells after treatment were detected in clone HeLa 776-6 than in control clone HeLa mock by applying the annexin staining ( Figure 6b ). Moreover, more cells were arrested in G2/ M in HeLa 776-6 after the treatment with siPlk than in HeLa mock cells (Figure 6c , upper and lower panels). Taken together, the data strongly indicate that tumor cells containing less cyclin B1 molecules are more susceptible to further treatment of siPlk than the cells expressing normal cyclin B1 protein.
Taxol (Paclitaxel s ) is one of the very often used taxanes in multidrug regiments for the therapy of several solid tumors, and induces also G2/M arrest in treated cells. To define the response of cells with a lower level of cyclin B1, we treated HeLa 776-6 cells with taxol, compared to the control clone HeLa mock. As depicted in Figure 7a , at a high concentration, ranging from 100 ng/ml to 1 mg/ml, a strong inhibitory impact of taxol was shown in HeLa 776-6 cells as well as in HeLa mock cells. Intriguingly, the inhibition was stronger in HeLa 776-6 cells at low concentrations between 1 and 10 ng/ ml, whereas the effect was clearly less in HeLa mock. The results were further correlated with the cell cycle analysis: a G2/M arrest was more demonstrative in HeLa 776-6 cells than in control HeLa mock cells (Figure 7b) . Furthermore, the percentage of the sub-G1 population of HeLa 776-6 treated with low concentration (1 ng/ml) taxol was much higher than that of the control HeLa or HeLa mock cells with the same treatment (Figure 7b , lower panel), suggesting that more HeLa 776-6 cells went to apoptosis with low dose taxol.
Tumor growth of HeLa 776-6 cells was reduced in nude mice To address whether cyclin B1 is required for the aggressive growth of tumor in vivo, we performed the xenograft experiment in nude mice. Each group of six mice was inoculated with HeLa 776-6 cells or its control HeLa mock cells. As shown in Figure 8a , tumor growth of HeLa 776-6 was inhibited, in comparison with the control HeLa mock. The data suggest that cyclin B1 is indeed required in vivo for promoting proliferation of tumor cells and the reduction of cyclin B1 slows down the tumor growth. Phenotype and in vivo relevance of the reduction of cyclin B1 J Yuan et al Subsequently, the tumor samples from mice were further examined. We could show that HeLa 776-6 contained less cyclin B1 protein than HeLa mock (Figure 8b) , indicating that the expression of shRNAs was still in function in vivo, and the inhibition of tumor growth was mainly resulted from the reduced cyclin B1 in tumor tissues.
Discussion
The uncontrolled cell cycle, leading to aggressive proliferation, is one of the most striking features in human tumors. Targeting the regulators of cell cycle, such as Cdks and cyclin D, has been attracting enormous attention in antitumor therapy. However, Phenotype and in vivo relevance of the reduction of cyclin B1 J Yuan et al recent investigations provided unexpected results: the fetal development of the mice occurs normally, in which the genes encoding three D-type cyclins, or two E-type cyclins, or Cdk4 and Cdk6, or cyclin E-dependent Cdk2 have been disrupted in the germ lines (Sherr and Roberts, 2004) . It seems that none of these genes can be strictly regarded as essential any more for cell cycle progression. Consequently, the impact of downregulation of those molecules for antitumor therapy should also be reconsidered. Conversely, the deletion of cyclin B1 resulted in embryonic lethality in the mouse, whereas cyclin B2 appears to be dispensable (Brandeis et al., 1998) . Moreover, we demonstrated in our previous report that the depletion of cyclin B1 generated tumorspecific apoptosis that was not observed in normal control cells (Yuan et al., 2004) , suggesting cyclin B1 is indispensable for tumor cell survival and its aggressive proliferation. Hence, the data shift more weight to cyclin B1 as an essential cell cycle regulator as well as a potential target for antiproliferative therapy. Reinforcement of cyclin B1 as a candidate for antitumor therapy comes from numerous clinical investigations. Overexpression of cyclin B1 has been reported in various malignant tumors including gastric cancer, colorectal cancer, head and neck squamous cell carcinoma and non-small-cell lung cancer (Soria et al., 2000; Hassan et al., 2001 Hassan et al., , 2002 Korenaga et al., 2002; Takeno et al., 2002; Yasuda et al., 2002; Yoshida et al., 2004) . Cyclin B1 has been shown to be a poor prognostic factor in some of the tumors (Soria et al., 2000; Hassan et al., 2001 Hassan et al., , 2002 Takeno et al., 2002) . In head and neck squamous cell carcinoma, overexpression of cyclin B1 is connected with the resistance to radiotherapy (Hassan et al., 2002) . Furthermore, overexpression of cyclin B1 was associated with histological grade of differentiation and vascular invasion (Yoshida et al., 2004) . Interestingly, there is a clinical correlation between the overexpression of cyclin B1 and the earlystage of non-small-cell lung cancer, particularly the squamous subtype (Soria et al., 2000) . Finally, elevated levels of cyclin B1 often precede the onset of tumor cell immortalization and aneuploidy (Chang and Schlegel, 1996; Kaufmann et al., 1997) , suggesting that the uncontrolled expression of cyclin B1 is an early event in the transformation process. The deregulation of cyclin B1, resulted from different mechanisms, is involved in the neoplastic transformation and promotes Phenotype and in vivo relevance of the reduction of cyclin B1 J Yuan et al the proliferation of tumor cells. Therefore, the clinical studies suggest that the downregulation of cyclin B1, subsequently the reduction of the kinase activity of Cdk1/cyclin B1, could become a specific promising intervention for tumor therapy .
In the present work, we established a cell model in which cyclin B1 is downregulated by applying stable transfection of the H1 promoter-driven shRNA constructs. We could demonstrate that cyclin B1 is specifically reduced in various levels, even lower than 1% (clone HeLa 776-6), compared to that in the control clone. The protein levels of other important regulators of G2/M transition, such as Cdk1, Cdc25C, Plk1 and cyclin A, remained unchanged, implying the reduction of cyclin B1 is specific and did not influence other G2/M molecules. Moreover, we analysed the phenotype of tumor cells with continuously downregulated cyclin B1. It is noted that HeLa 776-6 cells were arrested in G2 phase compared to control HeLa mock cells after 10 h release from the double-thymidine block. Cells, which Phenotype and in vivo relevance of the reduction of cyclin B1 J Yuan et al entered mitosis, showed abnormal chromosomal morphologies including reduced condensation and misalignment, which could trigger the mitotic catastrophe in tumor cells. Consistent with our previous data, we could show that the reduction of cyclin B1 slowed down proliferation rate by arresting cells in G2 phase and by inducing apoptosis. The later could be generated by many factors, such as the reduction of apoptotic inhibitors survivin and XIAP, as shown in Figure 4C and D. Further studies are required to explore the mechanisms by which the downregulation of cyclin B1 triggers apoptotic pathways in tumor cells. Moreover, while the control HeLa mock cells were progressively growing, the tumor growth of HeLa 776-6 cells was strongly inhibited in nude mice, which could be generated by the G2 arrest, the induction of apoptosis and other possible impairments involving cell viability and motility. Taken together, the data strengthen that cyclin B1 is required for the survival and proliferation of tumor cells and the depletion/downregulation of cyclin B1 inhibits proliferation of tumor cells in vitro as well as in vivo.
Intriguingly, the cell clone HeLa 776-6 containing reduced cyclin B1 was more susceptible to the treatment of siRNA targeting Plk1 or taxol. Like cyclin B1, Plk1 is also responsible for G2/M transition and for the progression through the mitosis. As shown in this study, targeting both molecules Plk1 and cyclin B1 will perturb the entry into mitosis and many stages of mitotic process and enforce their inhibitory impact on proliferation in HeLa tumor cells. Taxol is one of the taxanes representing the most important class of anticancer agents obtained from plants and is integrated in multidrug regiments for the therapy of several solid tumors. Taxol binds to b-tubulin subunits, inhibits microtubule dynamics and blocks cell cycle progression at the metaphase/anaphase transition (Jordan and Wilson, 2004) . Despite the relevant contribution of taxol in ameliorating the quality of life and overall survival of cancer patients, drug resistance and its side effects hamper its wide usage. Interestingly, in comparison with control clone HeLa mock, HeLa 776-6 displayed more sensibility, especially at a low dose of taxol. The observations imply that the combination of two agents, blocking the entry into mitosis by downregulation of cyclin B1 and targeting the transition of metaphase to anaphase by taxol, could improve the inhibitory effect on proliferation of tumor cells and reduce the dosage of taxol, subsequently the side effects of taxol.
Cdk1, the catalytic partner of cyclin B1, has been considered as a good candidate to be targeted for tumor therapy by both the academia and the pharmaceutical industry. The small molecule compounds inhibiting the activity of Cdk1 are well investigated including one prominent inhibitor Flavopiridol, which is already in clinical trials (Hunter and Pines, 1994; Garrett and Fattaey, 1999; Carnero, 2002; Senderowicz, 2003) . However, most inhibitors of Cdk1 are targeting the ATP binding site, which is conserved in Cdks and other members of the kinase family, leading often to an unintentional and unwished inhibition of other kinases. Alternatively, targeting cyclin B1, the regulatory partner of Cdk1 and an essential molecule for cell division, could be more selectively targeting the activity of Cdk1/ cyclin B1, as demonstrated by this study.
In summary, in this work we show that the reduction of cyclin B1 by applying stably transfected shRNA constructs targeting cyclin B1 inhibits the proliferation of HeLa cells in vitro as well as in vivo by causing sustained apoptosis and arresting the cells in the G2 phase. Targeting cyclin B1, in combination with other agents, could become an attractive alternative strategy for potential antitumor therapy.
Materials and methods
Cell culture, synchronization and cellular extract preparation The cervix carcinoma cell line HeLa was obtained from DSMZ (Braunschweig). MEM, Opti-MEM I, Oligofectamine, glutamine, penicillin, streptomycin and trypsin were obtained from Invitrogen (Karlsruhe). Fetal calf serum (FCS) was purchased from PAA laboratories (Co¨lbe). HeLa cells were cultured according to the supplier's instructions. HeLa cells were synchronized to the G1/S boundary by double-thymidine Phenotype and in vivo relevance of the reduction of cyclin B1 J Yuan et al block. Briefly, cells were treated with 2 mM thymidine for 16 h, released by washing cells with fresh medium for 8 h and subjected again to thymidine for a further 16 h. To obtain G2/ M arrest, after initial thymidine incubation and 8 h release, cells were exposed to 50 ng/ml nocodazole for 14 h. Cell lysis was performed in RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% Na-desoxycholate, 0.1% SDS, 1 mM Na 3 VO 4 , 1 mM PMSF, 1 mM DTT, 1 mM NaF, and protease inhibitor cocktail Complete (Roche, Mannheim)).
ShRNA constructs cloning and stable transfection
The DNA fragment for the expression of shRNA targeting the positions 776-796 of human cyclin B1 (NCBI accession number NM 031966) or for control shRNA against green fluorescent protein (GFP) was generated by annealing the sense oligonucleotide GTCGGATCCGAAATGTACCCTCC AGAAATTGAATTCGTTTCTGGAGGGTACATTTCTTT TTAAGCTTAGT and its antisense oligonucleotide (shRNA/ cyclin B1), or sense oligonucleotide CTCGGATCCGCTGAC CCTGAAGTTCATCTTGAATTCGGATGAACTTCAGGG TCAGCTTTTTAAGCTTCGA and its antisense oligo nucleotide (shRNA/GFP), respectively. After digestion with Bam HI and Hind III, the fragments were inserted into a phH1 vector, derived from a pEGFP-C2 vector (BD Biosciences, Heidelberg) as described previously (Matthess et al., 2005) . Transfection was performed using FuGENE6 transfection reagent according to the manufacturer's instructions (Roche, Mannheim). The cells were further cultured for 6 weeks in G418 (1.5 mg/ml) selective medium. After 6 weeks, the cell clones were chosen at random and seeded for further proliferation for Western blotting analysis in G418-containing medium.
To confirm that resistant clones contain integrated plasmid DNA including promoter and the shRNA-coding region, genomic DNA was prepared using a DNA Blood Kit, according to the manufacturer's instruction (Qiagen, Hilden). Then PCR analysis was performed by using sense primer of 5 0 -CGCCCTGCAATATTTGCATG-3 0 binding the H1 promoter at 5 0 position and antisense primer of 5 0 -CCGTCGACTGCA GAATTCGAAGC-3 0 binding to a plasmid-derived 3 0 sequence. Genomic DNA from nontransfected HeLa cells or plasmid DNA (phH1/shRNA/cyclinB1) was used as negative or positive control, respectively.
Western blot analysis
Total protein was separated by using 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA). Membranes were exposed to corresponding antibodies for 1 h in PBS containing 5% slim milk, washed with PBS, incubated subsequently with secondary antibodies for 1 h. Finally, the protein bands were visualized with the enhanced chemiluminescence reagent (ECL) (Pierce, Rockford). Mouse monoclonal antibodies against cyclin B1 (1:3000), Cdk1 (1:2000), rabbit polyclonal antibodies against cyclin A (1:3000), monoclonal antibodies against survivin (1:1000), monoclonal antibodies against p38 (1:1000) and goat antimouse or anti-rabbit secondary antibodies (1:2000) were purchased from Santa Cruz (Heidelberg). Mouse monoclonal antibodies against b-actin (1:200 000) were obtained from Sigma-Aldrich (Taufkirchen). Polyclonal antibodies against XIAP (1:1000) were from R&D systems. The Western blots were quantified by applying a Kodak gel documentation system (model 1D 3.5) and standardized with the loading controls.
Cell proliferation, analysis of cell cycle, apoptosis assay and subcellular localization of cyclin B1 All experiments were performed in triplicate. Cell viability was assessed by trypan blue staining. The proliferation rate of cells was determined at indicated time points by counting cell number with a hemacytometer. Cell cycle was analysed using a FACS apparatus (BD Biosciences, Heidelberg), as described (Yuan et al., 2002a) . Apoptosis was assessed using Vybrantt apoptosis assay kit (annexin V and propidium iodide staining) according to manufacturer's instruction (Molecular Probes, Leiden). Indirect immunofluorescence for subcellular cyclin B1 localization and DNA staining was carried out as previously described (Yuan et al., 2002a) .
In vitro kinase assay and soft-agar colony formation assay Antibodies against cyclin B1 (Santa Cruz, Heidelberg) were used for immunoprecipitation from 600 mg of cellular extracts. 0.5 mg histone H1 (Calbiochem, Darmstadt) served as substrate for each reaction. Kinase assays were performed as previously described (Yuan et al., 2002a) .
Colony-forming assays were performed using standard methods. Briefly, cells were seeded in 24-well plates at a density of 200 cells/well into culture medium containing 0.3% agar (Roth, Karlsruhe) overlaying 0.5% agar. Cells were cultured at 371C with 5% CO 2 , and colonies were counted 3-4 weeks later using a microscope (Zeiss, Oberkochen) . The colony number in control sample was referred as 100% by quantification.
Treatment with siRNA targeting Plk1(siPlk) and taxol Cells were seeded in 12-well plates the day before and treated with siRNAs or taxol for 48 h. siRNA targeting Plk1 (accession number X75932) corresponding to positions 1416-1438 was synthesized by Dharmacon Research, Inc. (Lafayette) (Spankuch-Schmitt et al., 2002) . Control siRNA targeting GFP (siGFP) was purchased from Dharmacon. Both siRNAs were 21 nucleotides in length and contained symmetric 3 0 overhangs of two deoxythymidines. Transient transfection was performed as described (Yuan et al., 2004) . Taxol was obtained from Mayne Pharma (Haar).
In vivo experiments and western blot analysis of tumor tissue Viable HeLa cells (1 Â 10 6 ) stably transfected with shRNA targeting cyclin B1 (clone HeLa 776-6) or the control shRNA against GFP (clone HeLa mock) were resuspended in 300 ml of 0.9% NaCl and subcutaneously injected into both flanks of nude mice. Each group contained six mice. Three weeks after inoculation, the tumor area was calculated by multiplication of the greatest diameter with the perpendicular diameter every 3-4 days. Measurements of all tumors within the group were represented by the mean value. Mann-Whitney U tests were performed for statistical evaluation of significant differences between two groups. All mice were properly treated in accordance with the guidelines of the local animal committee.
Cellular extracts from tumor tissues were prepared by using standard protocol. Briefly, tumor pieces were digested in lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 10% glycerol, 0.1% Tween 20, 1 mM DTT, 10 mM b-glycerol-phosphate, 1 mM NaF, 0.1 mM Na 3 VO 4 with protease inhibitor cocktail complete (Roche, Mannheim)), and then homogenized. After 30 min incubation on ice the lysates were centrifuged with 10 000 Â g at 41C for 20 min. Cellular extracts were obtained by further 20 min incubation on ice and centrifugation.
